Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MetAP2 is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins, a critical step in protein maturation and function. It plays an essential role in the regulation of protein synthesis by cotranslationally removing the initiator methionine. MetAP2 regulates angiogenesis, making it a target for anti-cancer therapies. Inhibitors targeting MetAP2 have shown efficacy in reducing hunger and inducing weight loss, leading to investigations into its potential use against metabolic diseases like type 2 diabetes.
Irreversible inhibition of MetAP2's activity at its active site.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methionine aminopeptidase type 2 (MetAP2).